How much profit has Innovative Pharmaceutical Biotech made this year?
Innovative Pharmaceutical Biotech has made 103.4 M HKD this year.
Innovative Pharmaceutical Biotech Net Income 2024
Innovative Pharmaceutical Biotech Net Income
103.4 M HKD
Ticker
399.HK
ISIN
BMG4783W1073
WKN
A1416X
In 2024, Innovative Pharmaceutical Biotech's profit amounted to 103.4 M HKD, a -142.09% increase from the -245.7 M HKD profit recorded in the previous year.
The Innovative Pharmaceutical Biotech Net Income history
| YEAR | NET INCOME (undefined HKD) |
|---|---|
| 2024 | 103.4 |
| 2023 | -245.7 |
| 2022 | 45.8 |
| 2021 | -204.94 |
| 2020 | -211.12 |
| 2019 | -260.27 |
| 2018 | -231.05 |
| 2017 | -169.79 |
| 2016 | -236.87 |
| 2015 | -451.68 |
| 2014 | -550.3 |
| 2013 | -72.8 |
| 2012 | -123.9 |
| 2011 | 4.9 |
| 2010 | 11.3 |
| 2009 | 476.2 |
| 2008 | -68.6 |
| 2007 | -64.2 |
| 2006 | -53 |
| 2005 | -41 |
Innovative Pharmaceutical Biotech Revenue, EBIT, Net Income BMG4783W1073 · A1416X
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Innovative Pharmaceutical Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Innovative Pharmaceutical Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Innovative Pharmaceutical Biotech’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Innovative Pharmaceutical Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Innovative Pharmaceutical Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Innovative Pharmaceutical Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Innovative Pharmaceutical Biotech’s growth potential.
Innovative Pharmaceutical Biotech Revenue, EBIT and net profit per share
| Date | Innovative Pharmaceutical Biotech Revenue | Innovative Pharmaceutical Biotech EBIT | Innovative Pharmaceutical Biotech Net Income |
|---|---|---|---|
| 2024 | 6.59 M HKD | -13.43 M HKD | 103.4 M HKD |
| 2023 | 8.08 M HKD | -20.75 M HKD | -245.7 M HKD |
| 2022 | 11.15 M HKD | -24.27 M HKD | 45.8 M HKD |
| 2021 | 15.19 M HKD | -21.66 M HKD | -204.94 M HKD |
| 2020 | 14.58 M HKD | -32.58 M HKD | -211.12 M HKD |
| 2019 | 18.59 M HKD | -26.66 M HKD | -260.27 M HKD |
| 2018 | 15.81 M HKD | -25.6 M HKD | -231.05 M HKD |
| 2017 | 9.19 M HKD | -22.49 M HKD | -169.79 M HKD |
| 2016 | 19.91 M HKD | -37.94 M HKD | -236.87 M HKD |
| 2015 | 33.98 M HKD | -42.76 M HKD | -451.68 M HKD |
| 2014 | 29.7 M HKD | -37.2 M HKD | -550.3 M HKD |
| 2013 | 10.1 M HKD | -69.7 M HKD | -72.8 M HKD |
| 2012 | 25.5 M HKD | -42.1 M HKD | -123.9 M HKD |
| 2011 | 90.2 M HKD | 6.5 M HKD | 4.9 M HKD |
| 2010 | 483.9 M HKD | 13.3 M HKD | 11.3 M HKD |
| 2009 | 374.4 M HKD | 612.2 M HKD | 476.2 M HKD |
| 2008 | 317 M HKD | -8.6 M HKD | -68.6 M HKD |
| 2007 | 83.1 M HKD | -3.7 M HKD | -64.2 M HKD |
| 2006 | 32 M HKD | -3 M HKD | -53 M HKD |
| 2005 | 29.1 M HKD | -5.9 M HKD | -41 M HKD |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 29.1 M HKD | -5.9 M HKD | -41 M HKD |
| 2006 | 32 M HKD | -3 M HKD | -53 M HKD |
| 2007 | 83.1 M HKD | -3.7 M HKD | -64.2 M HKD |
| 2008 | 317 M HKD | -8.6 M HKD | -68.6 M HKD |
| 2009 | 374.4 M HKD | 612.2 M HKD | 476.2 M HKD |
| 2010 | 483.9 M HKD | 13.3 M HKD | 11.3 M HKD |
| 2011 | 90.2 M HKD | 6.5 M HKD | 4.9 M HKD |
| 2012 | 25.5 M HKD | -42.1 M HKD | -123.9 M HKD |
| 2013 | 10.1 M HKD | -69.7 M HKD | -72.8 M HKD |
| 2014 | 29.7 M HKD | -37.2 M HKD | -550.3 M HKD |
| 2015 | 33.98 M HKD | -42.76 M HKD | -451.68 M HKD |
| 2016 | 19.91 M HKD | -37.94 M HKD | -236.87 M HKD |
| 2017 | 9.19 M HKD | -22.49 M HKD | -169.79 M HKD |
| 2018 | 15.81 M HKD | -25.6 M HKD | -231.05 M HKD |
| 2019 | 18.59 M HKD | -26.66 M HKD | -260.27 M HKD |
| 2020 | 14.58 M HKD | -32.58 M HKD | -211.12 M HKD |
| 2021 | 15.19 M HKD | -21.66 M HKD | -204.94 M HKD |
| 2022 | 11.15 M HKD | -24.27 M HKD | 45.8 M HKD |
| 2023 | 8.08 M HKD | -20.75 M HKD | -245.7 M HKD |
| 2024 | 6.59 M HKD | -13.43 M HKD | 103.4 M HKD |
Innovative Pharmaceutical Biotech stock margins BMG4783W1073 · A1416X
The Innovative Pharmaceutical Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innovative Pharmaceutical Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innovative Pharmaceutical Biotech.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Innovative Pharmaceutical Biotech's sales revenue. A higher gross margin percentage indicates that the Innovative Pharmaceutical Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Innovative Pharmaceutical Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Innovative Pharmaceutical Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Innovative Pharmaceutical Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Innovative Pharmaceutical Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Innovative Pharmaceutical Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Innovative Pharmaceutical Biotech Margin History
| Innovative Pharmaceutical Biotech Gross margin | Innovative Pharmaceutical Biotech Profit margin | Innovative Pharmaceutical Biotech EBIT margin | Innovative Pharmaceutical Biotech Profit margin |
|---|---|---|---|
| 2024 | 12.74 % | -203.75 % | 1,568.38 % |
| 2023 | 10.63 % | -256.97 % | -3,042.7 % |
| 2022 | 9.46 % | -217.8 % | 410.97 % |
| 2021 | 9.25 % | -142.58 % | -1,349.26 % |
| 2020 | 11.11 % | -223.47 % | -1,447.99 % |
| 2019 | 9.4 % | -143.39 % | -1,400.14 % |
| 2018 | 8.82 % | -161.88 % | -1,461.31 % |
| 2017 | 7.91 % | -244.78 % | -1,848.13 % |
| 2016 | 2.96 % | -190.58 % | -1,189.8 % |
| 2015 | 2.7 % | -125.86 % | -1,329.42 % |
| 2014 | -2.02 % | -125.25 % | -1,852.86 % |
| 2013 | -79.21 % | -690.1 % | -720.79 % |
| 2012 | 59.22 % | -165.1 % | -485.88 % |
| 2011 | 37.14 % | 7.21 % | 5.43 % |
| 2010 | 8.47 % | 2.75 % | 2.34 % |
| 2009 | 3.07 % | 163.51 % | 127.19 % |
| 2008 | 2.56 % | -2.71 % | -21.64 % |
| 2007 | 4.81 % | -4.45 % | -77.26 % |
| 2006 | 13.13 % | -9.38 % | -165.63 % |
| 2005 | 11.68 % | -20.27 % | -140.89 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 11.68 % | -20.27 % | -140.89 % |
| 2006 | 13.13 % | -9.38 % | -165.63 % |
| 2007 | 4.81 % | -4.45 % | -77.26 % |
| 2008 | 2.56 % | -2.71 % | -21.64 % |
| 2009 | 3.07 % | 163.51 % | 127.19 % |
| 2010 | 8.47 % | 2.75 % | 2.34 % |
| 2011 | 37.14 % | 7.21 % | 5.43 % |
| 2012 | 59.22 % | -165.1 % | -485.88 % |
| 2013 | -79.21 % | -690.1 % | -720.79 % |
| 2014 | -2.02 % | -125.25 % | -1,852.86 % |
| 2015 | 2.7 % | -125.86 % | -1,329.42 % |
| 2016 | 2.96 % | -190.58 % | -1,189.8 % |
| 2017 | 7.91 % | -244.78 % | -1,848.13 % |
| 2018 | 8.82 % | -161.88 % | -1,461.31 % |
| 2019 | 9.4 % | -143.39 % | -1,400.14 % |
| 2020 | 11.11 % | -223.47 % | -1,447.99 % |
| 2021 | 9.25 % | -142.58 % | -1,349.26 % |
| 2022 | 9.46 % | -217.8 % | 410.97 % |
| 2023 | 10.63 % | -256.97 % | -3,042.7 % |
| 2024 | 12.74 % | -203.75 % | 1,568.38 % |
Innovative Pharmaceutical Biotech Aktienanalyse
What does Innovative Pharmaceutical Biotech do?
The company Innovative Pharmaceutical Biotech Ltd is a company that is active in the field of biotechnological and pharmaceutical research and development. The company has its roots in the research and development of innovative active substances and drugs. The company's history began in the 1990s, when a group of scientists came together to bundle their expertise and visions and develop innovative solutions in the field of active substance research. They founded Innovative Pharmaceutical Biotech Ltd as an independent company in 2000. The company's business model is based on the research and development of new active substances and drugs in the field of oncology, neurology, and immunology. The company follows an insistence-driven approach, aiming to develop active substances with innovative mechanisms of action that are superior to proven therapeutic approaches. Innovative Pharmaceutical Biotech Ltd collaborates with a broad network of partners and cooperation partners, including academic research institutions, clinical centers, biotech companies, and pharmaceutical companies. The company cooperates with companies from all over the world and operates worldwide. The company has various divisions, each focusing on the development of active substances and drugs in specific medical fields. In the oncology division, the company develops active substances and drugs for the treatment of cancer. In the neurology division, active substances and drugs for the treatment of neurological diseases such as Alzheimer's and Parkinson's are researched and developed. The immunology division of the company is dedicated to the development of active substances and drugs for the treatment of immune system diseases such as autoimmune diseases and inflammations. Over the years, the company has developed and launched a number of products. One of its most important products is an active substance for the treatment of breast cancer, which has shown promising results in clinical studies. The company has also developed a treatment for the relief of pain in cancer and other patients based on chemotherapy symptoms. In addition to its research and development efforts, Innovative Pharmaceutical Biotech Ltd attaches great importance to compliance with standards and regulations in the pharmaceutical and biotechnological industry. The company maintains strict quality control procedures and strives to adhere to the highest standards in drug manufacturing. Innovative Pharmaceutical Biotech Ltd sees itself as a pioneer in the pharmaceutical and biotechnological industry and takes pride in developing innovative solutions that have the potential to improve the lives of people around the world. The company has a variety of partners and cooperation partners worldwide and is proud to have a global presence in the field of biotechnological and pharmaceutical research and development. In summary, Innovative Pharmaceutical Biotech Ltd is a company that focuses on the research and development of innovative active substances and drugs that have the potential to improve the lives of people worldwide. The company collaborates with a broad network of partners and cooperation partners and maintains strict quality control procedures to adhere to the highest standards in drug manufacturing. The translation is as accurate as possible. Innovative Pharmaceutical Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Innovative Pharmaceutical Biotech's Profit Margins
The profit margins of Innovative Pharmaceutical Biotech represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Innovative Pharmaceutical Biotech's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Innovative Pharmaceutical Biotech's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Innovative Pharmaceutical Biotech's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Innovative Pharmaceutical Biotech’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Innovative Pharmaceutical Biotech stock
How has the profit developed compared to last year?
The profit has increased by -142.09% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Innovative Pharmaceutical Biotech publish its earnings?
Innovative Pharmaceutical Biotech publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Innovative Pharmaceutical Biotech?
The profits of Innovative Pharmaceutical Biotech are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Innovative Pharmaceutical Biotech?
You can learn more about the earnings of Innovative Pharmaceutical Biotech by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Innovative Pharmaceutical Biotech pay?
Over the past 12 months, Innovative Pharmaceutical Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innovative Pharmaceutical Biotech is expected to pay a dividend of 0 HKD.
What is the dividend yield of Innovative Pharmaceutical Biotech?
The current dividend yield of Innovative Pharmaceutical Biotech is .
When does Innovative Pharmaceutical Biotech pay dividends?
Innovative Pharmaceutical Biotech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Innovative Pharmaceutical Biotech?
Innovative Pharmaceutical Biotech paid dividends every year for the past 0 years.
What is the dividend of Innovative Pharmaceutical Biotech?
For the upcoming 12 months, dividends amounting to 0 HKD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Innovative Pharmaceutical Biotech located?
Innovative Pharmaceutical Biotech is assigned to the 'Industry' sector.
Wann musste ich die Aktien von Innovative Pharmaceutical Biotech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Innovative Pharmaceutical Biotech from 12/31/2003 amounting to 0.02 HKD, you needed to have the stock in your portfolio before the ex-date on 12/10/2003.
When did Innovative Pharmaceutical Biotech pay the last dividend?
The last dividend was paid out on 12/31/2003.
What was the dividend of Innovative Pharmaceutical Biotech in the year 2023?
In the year 2023, Innovative Pharmaceutical Biotech distributed 0 HKD as dividends.
In which currency does Innovative Pharmaceutical Biotech pay out the dividend?
The dividends of Innovative Pharmaceutical Biotech are distributed in HKD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Innovative Pharmaceutical Biotech
Our stock analysis for Innovative Pharmaceutical Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innovative Pharmaceutical Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Innovative Pharmaceutical Biotech Revenue
- Innovative Pharmaceutical Biotech Net Income
- Innovative Pharmaceutical Biotech P/E
- Innovative Pharmaceutical Biotech P/S
- Innovative Pharmaceutical Biotech EBIT
- Innovative Pharmaceutical Biotech Dividend
- Innovative Pharmaceutical Biotech Stocks
- Innovative Pharmaceutical Biotech Market capitalization
- Innovative Pharmaceutical Biotech Debt
- Innovative Pharmaceutical Biotech Liabilities
- Innovative Pharmaceutical Biotech Equity
- Innovative Pharmaceutical Biotech AAQS
- Innovative Pharmaceutical Biotech Employees
- Innovative Pharmaceutical Biotech ROE
- Innovative Pharmaceutical Biotech ROA
- Innovative Pharmaceutical Biotech ROCE
